Do cannabinoids provide neuroprotection Multiple Sclerosis Biology essay
Background: To date, the majority of people diagnosed with MS experience disabling symptoms, such as spasticity and neuropathic pain, during the course of the disease. Because first-line symptomatic therapy is associated with significant side effects, cannabinoids have become increasingly popular among patients with MS. Background: Evidence suggests that exercise has the potential to counteract neurodegeneration experienced by people with multiple sclerosis pwMS, which is thought to be mediated in part by an increase in neurotrophic factors. It is necessary to summarize the existing evidence on exercise-induced effects on neurotrophs. The effect of cannabinoids has been studied on the retina, cornea and eye motility. Cannabinoids are involved in two different treatment approaches, including directly lowering IOP or via neuroprotection independent of IOP to improve and slow disease progression. Multiple sclerosis MS is a complex neurological disorder involving both inflammatory demyelinating and neurodegenerative components. MS research and treatments have traditionally focused on immune modulation, with less research on neuroprotection, and this includes the role of vitamin D in MS. Researchers have said that cannabinoids are the chemical components of cannabis. They act as messengers, interacting with the endocannabinoid system in our body and acting on receptors that can help regulate mood, memory, appetite and pain. Additionally, cannabinoids activate receptors throughout the body, affecting the central nervous system. Cannabinoids have recently attracted renewed interest in their therapeutic applications, with increasing evidence for their role in symptom management in MS. Cannabinoids exert their role through the endogenous cannabinoid ECB system, with some reports shedding light on the molecular biology of this system and lending credence to some. Tryptophan 2,3-dioxygenase TDO deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis. Science Rep. 7, 41271 doi: 10.1038 srep41271 2017. Because animal studies provide more detailed mechanistic information on the pathobiology of neuroinflammation and remyelination than is possible from human studies, the second part of this article discusses the effects of using cannabinoids in various experimental animal models. from MS. Studies assessed clinical disease values. Cannabinoids may provide symptom control in multiple sclerosis MS. We show here that cannabinoid receptor CBR agonists can also be immunosuppressive and neuroprotective in MS models. Immunosuppression was associated with reduced: myelin-specific T cell responses, central nervous system infiltration and reduced clinical disease. The use of cannabinoids as a treatment option for glaucoma has not yet been approved due to the lack of supporting clinical studies and due to unwanted side effects. However, it offers a promising therapeutic intervention in the progression and onset of glaucoma, either by lowering IOP and/or through neuroprotection. Cannabinoids appear to be well tolerated in medicinal use. Side effects generally appear to be mild, and most serious side effects from clinical trials do not appear to be related to, or expected to result from, the complications of MS. Greenberg et al. evaluated the effect of smoking marijuana on balance in ten patients with MS and described:.